Asia-Pacific Herpes Market, By Virus Type (Herpes Simplex and Herpes Zoster), Product (Acyclovir, Docosanol, Valacyclovir, Famciclovir and Others), Drug Type (Prescription Drug and Over-the-counter Drug), Age (Adult and Pediatrics), Route Of Administration (Topical, Oral, and Parenteral), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies, and Others), End Users (Hospitals, Speciality Clinics, and Others) Country (China, India, Japan, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia Philippines and Rest of Asia-Pacific) Industry Trends and Forecast to 2028.
Market Analysis and Insights: Asia-Pacific Herpes Market
Asia-Pacific herpes market is expected to gain significant growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyzes that the Asia-Pacific herpes market is growing with a CAGR of 5.6% in the forecast period of 2021 to 2028 and is expected to reach USD 269.74 million by 2028 from USD 181.72 million in 2020. Rising prevalence of herpes infections and increasing geriatric population are major drivers, which are expected to boost the growth of the market in the forecast period.
A growing number of people are affected with by the herpes simplex virus, which demands highly effective and advanced anti-herpetic treatment to minimize the risk during the treatment. The healthcare systems need highly advanced drugs for numerous different types of herpes during the treatment of patients. Therefore, major market players are highly focusing on product launches and product approvals. Additionally, governments and regulatory bodies are supporting market players by virtue of product approvals.
Rising prevalence of herpes diseases and increase in health expenditure across regions have accelerated the need for anti-herpetic drugs in healthcare facilities, which is driving the growth of the herpes market. In addition, surging volume of geriatric people is further propelling the market growth. However, high cost of anti-herpetic medicines and product recalls are anticipated to hinder market growth in the projected period. On the other hand, strategic initiatives by market players and soaring number of anti-herpetic drugs manufacturers act as an opportunity for this market and is expected to impel the market growth. However, disruption in supply chain of herpes drugs and injections during covid-19 and lack of workforce in pharma industries are key challenges for this market.
The Asia-Pacific herpes market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.
The Asia-Pacific Herpes Market Scope and Market Size
The Asia-Pacific herpes market is segmented on the basis of virus type, product, drug type, age, route of administration, distribution channel, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of virus type, the Asia-Pacific herpes market is segmented into herpes simplex and herpes zoster. In 2021, herpes simplex segment is expected to dominate the market due to rise in prevalence of herpes infections owing to unprotected sex with an infected partner.
- On the basis of product, the Asia-Pacific herpes market is segmented into acyclovir, docosanol, valacyclovir, famciclovir, and others. In 2021, acyclovir segment is expected to dominate the market due to increasing launch of new drugs by pharmaceutical manufacturers.
- On the basis of drug type, the Asia-Pacific herpes market is segmented into prescription drug and over-the counter drug. In 2021, prescription drug segment is expected to dominate the market owing to growing pharmaceutical market in the region.
- On the basis of age, the Asia-Pacific herpes market is segmented into adult and pediatrics. In 2021, adult segment is expected to dominate the market owing to rising geriatric population In China, Japan, and India.
- On the basis of route of administration, the Asia-Pacific herpes market is segmented into topical, oral, and parenteral. In 2021, topical segment is expected to dominate the market owing to greater patient compliance and better aid in quick healing.
- On the basis of distribution channel, the Asia-Pacific herpes market is segmented into hospitals pharmacies, retail pharmacies, drug stores, online pharmacies, and others. In 2021, hospital pharmacies segment is expected to dominate the market owing to wider availability of anti-herpetic drugs.
- On the basis of end-users, the Asia-Pacific herpes market is segmented into hospital, speciality clinics, and others. In 2021, hospitals segment is expected to dominate the market due to rising new product launches associated with this segment.
Asia-Pacific Herpes Market Country Level Analysis
The Asia-Pacific herpes market is analyzed and market size information is provided based on virus type, product, drug type, age, route of administration, distribution channel, and end users.
Countries covered in the Asia-Pacific herpes market report are China, India, Japan, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia Philippines, and Rest of Asia-Pacific. The Asia-Pacific region is expected to grow with the most promising growth rate in the forecast period of 2021 to 2028 because of rising prevalence geriatric population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Rising healthcare expenditure and high prevalence of herpes infections in the Asia-Pacific creating new opportunities for players in the Asia-Pacific herpes market
Herpes simplex segment is dominating in China, which is leading in the Asia-Pacific region owing to growing geriatric population in the country.
Asia-Pacific herpes market also provides you with detailed market analysis for every country growth in particular industry with the Asia-Pacific herpes market sales, impact of advancement in the Asia-Pacific herpes market and changes in regulatory scenarios with their support for the Asia-Pacific herpes market. The data is available for historic period 2010 to 2018.
Competitive Landscape and Asia-Pacific herpes market Share Analysis
Asia-Pacific herpes market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, and technology lifeline curve. The above data points provided are only related to the companies’ focus related to Asia-Pacific herpes market.
Major players covered in the report are Abbott, Apotex, Inc., Avet Pharmaceuticals, Inc., Bausch Health Companies, Inc. Cipla, Inc., Dr. Reddy’s Laboratories Ltd., EPI Health, Fresenius Kabi AG, GlaxoSmithKline plc., Glenmark Pharmaceutical Inc., USA, Maruho Co.,Ltd., Mylan N.V., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Zydus Pharmaceuticals, Inc., RECORDATI S.p.A., Aurobindo Pharma, Amneal Pharmaceuticals LLC, Slavia Pharm S.R.L., and Blistex, Inc., among others domestic and Asia-Pacific players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product launches and agreements are also initiated by the companies worldwide, which are further accelerating the growth of the Asia-Pacific herpes market.
For instance,
- In November 2019, In November, Mylan N.V. announced the combination of the company with Upjohn, a division of Pfizer, the new company formed would be named Viatris. The merger of both the companies to develop a combined firm has expanded its product portfolio leading to increased demand for its product in the market.
- In September 2018, Avet Pharmaceuticals Inc. announced the immediate availability of Acyclovir 200mg Capsules. This launch enhanced Avet’s broad portfolio of generic oral solid products. This new drug launched by the company has increased its sales and demand in the market, leading to increased revenue in the future. This helped the company increase its product line.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC HERPES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 VIRUS TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 SUMMARY WRITE UP (NORTH AMERICA)
4.1.1 OVERVIEW
4.2 SUMMARY WRITE UP (EUROPE)
4.2.1 OVERVIEW
4.3 SUMMARY WRITE UP (ASIA-PACIFIC)
4.3.1 OVERVIEW
4.4 SUMMARY WRITE UP (SOUTH AMERICA)
4.4.1 OVERVIEW
4.5 SUMMARY WRITE UP (MIDDLE EAST AND AFRICA)
4.5.1 OVERVIEW
5 ASIA-PACIFIC HERPES MARKET: REGULATIONS
5.1 THE U.S. REGULATORY FRAMEWORK
5.2 CANADA REGULATORY FRAMEWORK
5.3 THE EUROPE REGULATORY FRAMEWORK
5.4 INDIA REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.2 INCREASING GERIATRIC POPULATION
6.2.1 INCREASE IN PREVALENCE OF HERPES INFECTIONS
6.2.2 INCREASE IN NUMBER OF PRODUCT APPROVALS AND LAUNCHES
6.2.3 RISING NUMBER OF IMMUNOCOMPROMISED PEOPLE
6.3 RESTRAINTS
6.3.1 HIGH COST OF ANTI-HERPETIC MEDICINES
6.3.2 PRODUCT RECALL
6.4 OPPORTUNITIES
6.4.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
6.4.2 INCREASING HEALTHCARE EXPENDITURE
6.4.3 SOARING NUMBER OF ANTI-HERPETIC DRUGS MANUFACTURERS
6.4.4 RISE IN NUMBER OF CONTRACT MANUFACTURING ORGANIZATIONS (CMO) AND CONTRACT RESEARCH ORGANIZATIONS (CRO)
6.5 CHALLENGES
6.5.1 DISRUPTION IN THE SUPPLY CHAIN OF HERPES DRUGS AND INJECTIONS DURING COVID-19
6.5.2 LACK OF WORKFORCE IN PHARMA INDUSTRIES
7 IMPACT OF COVID-19 ON ASIA-PACIFIC HERPES MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 STRATEGIC DECISION BY MANUFACTURERS
7.5 CONCLUSION
8 ASIA-PACIFIC HERPES MARKET, BY VIRUS TYPE
8.1 OVERVIEW
8.2 HERPES SIMPLEX
8.2.1 TYPE I
8.2.2 TYPE II
8.3 HERPES ZOSTER
9 ASIA-PACIFIC HERPES MARKET, BY PRODUCT TYPE
9.1 OVERVIEW
9.2 ACYCLOVIR
9.3 DOCOSANOL
9.4 VALACYCLOVIR
9.5 FAMCICLOVIR
9.6 OTHERS
10 ASIA-PACIFIC HERPES MARKET, BY DRUG TYPE
10.1 OVERVIEW
10.2 PRESCRIPTION DRUG
10.3 OVER-THE COUNTER DRUG
11 ASIA-PACIFIC HERPES MARKET, BY AGE
11.1 OVERVIEW
11.2 ADULT
11.3 PEDIATRICS
12 ASIA-PACIFIC HERPES MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 TOPICAL
12.3 ORAL
12.4 PARENTERAL
13 ASIA-PACIFIC HERPES MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 HOSPITALS PHARMACIES
13.3 RETAIL PHARMACIES
13.4 DRUG STORES
13.5 ONLINE PHARMACIES
13.6 OTHERS
14 ASIA-PACIFIC HERPES MARKET, BY END USERS
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALITY CLINICS
14.4 OTHERS
15 ASIA-PACIFIC HERPES MARKET, BY REGION
15.1 ASIA-PACIFIC
15.1.1 CHINA
15.1.2 INDIA
15.1.3 JAPAN
15.1.4 SOUTH KOREA
15.1.5 AUSTRALIA
15.1.6 SINGAPORE
15.1.7 THAILAND
15.1.8 MALAYSIA
15.1.9 INDONESIA
15.1.10 PHILIPPINES
15.1.11 REST OF ASIA-PACIFIC
16 ASIA-PACIFIC HERPES MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 GLAXOSMITHKILNE PLC
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENT
18.2 VIATRIS INC.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.3 FRESENIUS KABI AG
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 PFIZER INC.
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.5 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENT
18.6 ABBOTT
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.7 AMNEAL PHARMACEUTICALS LLC
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 APOTEX INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.9 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA)
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENT
18.1 AVET PHARMACEUTICALS INC.
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 BAUSCH HEALTH COMPANIES INC.
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENT
18.12 BLISTEX, INC.
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENT
18.13 CIPLA, INC.
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 DR. REDDY’S LABORATORIES LTD.
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENT
18.15 EPIHEALTH
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENT
18.16 GLENMARK PHARMACEUTICAL INC., USA (A SUBSIDIARY OF GLENMARK PHARMACEUTICALS LTD.)
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENT
18.17 MARUHO CO.,LTD.
18.17.1 COMPANY SNAPSHOT
18.17.2 PRODUCT PORTFOLIO
18.17.3 RECENT DEVELOPMENTS
18.18 RECORDATI S.P.A.
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENT
18.19 SLAVIA PHARM S.R.L.
18.19.1 COMPANY SNAPSHOT
18.19.2 PRODUCT PORTFOLIO
18.19.3 RECENT DEVELOPMENT
18.2 SUN PHARMACEUTICAL INDUSTRIES LTD
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENT
18.21 ZYDUS PHARMACEUTICALS, INC.
18.21.1 COMPANY SNAPSHOT
18.21.2 PRODUCT PORTFOLIO
18.21.3 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
List of Table
LIST OF TABLES
TABLE 1 THE EMA HAS SEVEN SCIENTIFIC COMMITTEES THAT CARRY OUT ITS SCIENTIFIC ASSESSMENTS:
TABLE 2 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC
TABLE 3 MANUFACTURERS OF ANTI-HERPETIC DRUGS
TABLE 4 ASIA-PACIFIC HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 5 ASIA-PACIFIC HERPES SIMPLEX IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 ASIA-PACIFIC HERPES SIMPLEX IN HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC HERPES ZOSTER IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC HERPES MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC ACYCLOVIR IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC DOCOSANOL IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC VALACYCLOVIR IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC FAMCICLOVIR IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC OTHERS IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC HERPES MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC PRESCRIPTION DRUG IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC OVER-THE COUNTER DRUG IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC HERPES MARKET, BY AGE, 2019-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC ADULT IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC PEDIATRICS IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 ASIA-PACIFIC HERPES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC TOPICAL IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC ORAL IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC PARENTERAL IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC HERPES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC HOSPITALS PHARMACIES IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC RETAIL PHARMACIES IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC DRUG STORES IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 ASIA-PACIFIC ONLINE PHARMACIES IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 ASIA-PACIFIC OTHERS IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC HERPES MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC HOSPITALS IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 ASIA-PACIFIC SPECIALITY CLINICS IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 ASIA-PACIFIC OTHERS IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 ASIA-PACIFIC HERPES MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 35 ASIA-PACIFIC HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 36 ASIA-PACIFIC HERPES SIMPLEX IN HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 37 ASIA-PACIFIC HERPES MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 38 ASIA-PACIFIC HERPES MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 39 ASIA-PACIFIC HERPES MARKET, BY AGE, 2019-2028 (USD MILLION)
TABLE 40 ASIA-PACIFIC HERPES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 41 ASIA-PACIFIC HERPES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 42 ASIA-PACIFIC HERPES MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 43 CHINA HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 44 CHINA HERPES SIMPLEX IN HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 45 CHINA HERPES MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 46 CHINA HERPES MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 47 CHINA HERPES MARKET, BY AGE, 2019-2028 (USD MILLION)
TABLE 48 CHINA HERPES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 49 CHINA HERPES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 50 CHINA HERPES MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 51 INDIA HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 52 INDIA HERPES SIMPLEX IN HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 53 INDIA HERPES MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 54 INDIA HERPES MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 55 INDIA HERPES MARKET, BY AGE, 2019-2028 (USD MILLION)
TABLE 56 INDIA HERPES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 57 INDIA HERPES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 58 INDIA HERPES MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 59 JAPAN HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 60 JAPAN HERPES SIMPLEX IN HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 61 JAPAN HERPES MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 62 JAPAN HERPES MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 63 JAPAN HERPES MARKET, BY AGE, 2019-2028 (USD MILLION)
TABLE 64 JAPAN HERPES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 65 JAPAN HERPES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 66 JAPAN HERPES MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 67 SOUTH KOREA HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 68 SOUTH KOREA HERPES SIMPLEX IN HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 69 SOUTH KOREA HERPES MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 70 SOUTH KOREA HERPES MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 71 SOUTH KOREA HERPES MARKET, BY AGE, 2019-2028 (USD MILLION)
TABLE 72 SOUTH KOREA HERPES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 73 SOUTH KOREA HERPES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 74 SOUTH KOREA HERPES MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 75 AUSTRALIA HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 76 AUSTRALIA HERPES SIMPLEX IN HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 77 AUSTRALIA HERPES MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 78 AUSTRALIA HERPES MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 79 AUSTRALIA HERPES MARKET, BY AGE, 2019-2028 (USD MILLION)
TABLE 80 AUSTRALIA HERPES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 81 AUSTRALIA HERPES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 82 AUSTRALIA HERPES MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 83 SINGAPORE HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 84 SINGAPORE HERPES SIMPLEX IN HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 85 SINGAPORE HERPES MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 86 SINGAPORE HERPES MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 87 SINGAPORE HERPES MARKET, BY AGE, 2019-2028 (USD MILLION)
TABLE 88 SINGAPORE HERPES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 89 SINGAPORE HERPES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 90 SINGAPORE HERPES MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 91 THAILAND HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 92 THAILAND HERPES SIMPLEX IN HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 93 THAILAND HERPES MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 94 THAILAND HERPES MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 95 THAILAND HERPES MARKET, BY AGE, 2019-2028 (USD MILLION)
TABLE 96 THAILAND HERPES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 97 THAILAND HERPES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 98 THAILAND HERPES MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 99 MALAYSIA HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 100 MALAYSIA HERPES SIMPLEX IN HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 101 MALAYSIA HERPES MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 102 MALAYSIA HERPES MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 103 MALAYSIA HERPES MARKET, BY AGE, 2019-2028 (USD MILLION)
TABLE 104 MALAYSIA HERPES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 105 MALAYSIA HERPES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 106 MALAYSIA HERPES MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 107 INDONESIA HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 108 INDONESIA HERPES SIMPLEX IN HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 109 INDONESIA HERPES MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 110 INDONESIA HERPES MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 111 INDONESIA HERPES MARKET, BY AGE, 2019-2028 (USD MILLION)
TABLE 112 INDONESIA HERPES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 113 INDONESIA HERPES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 114 INDONESIA HERPES MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 115 PHILIPPINES HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 116 PHILIPPINES HERPES SIMPLEX IN HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 117 PHILIPPINES HERPES MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 118 PHILIPPINES HERPES MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 119 PHILIPPINES HERPES MARKET, BY AGE, 2019-2028 (USD MILLION)
TABLE 120 PHILIPPINES HERPES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 121 PHILIPPINES HERPES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 122 PHILIPPINES HERPES MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 123 REST OF ASIA-PACIFIC HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
List of Figure
LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC HERPES MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC HERPES MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC HERPES MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC HERPES MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC HERPES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC HERPES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC HERPES MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC HERPES MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 ASIA-PACIFIC HERPES MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC HERPES MARKET: SEGMENTATION
FIGURE 11 INCREASE IN PREVALENCE OF HERPES INFECTIONS AND RISE IN HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE ASIA-PACIFIC HERPES MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 HERPES SIMPLEX SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC HERPES MARKET IN 2021 & 2028
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC HERPES MARKET
FIGURE 14 NUMBER OF PERSON AGED 60 YEARS OR OVER BY REGIONS IN 2020 (IN MILLIONS)
FIGURE 15 MARKET GROWTH IN CLINICAL CRO (IN USD MILLIONS)
FIGURE 16 ASIA-PACIFIC HERPES MARKET : BY VIRUS TYPE, 2020
FIGURE 17 ASIA-PACIFIC HERPES MARKET : BY VIRUS TYPE, 2019-2028 (USD MILLION)
FIGURE 18 ASIA-PACIFIC HERPES MARKET : BY VIRUS TYPE, CAGR (2021-2028)
FIGURE 19 ASIA-PACIFIC HERPES MARKET : BY VIRUS TYPE, LIFELINE CURVE
FIGURE 20 ASIA-PACIFIC HERPES MARKET : BY PRODUCT TYPE, 2020
FIGURE 21 ASIA-PACIFIC HERPES MARKET : BY PRODUCT TYPE, 2019-2028 (USD MILLION)
FIGURE 22 ASIA-PACIFIC HERPES MARKET : BY PRODUCT TYPE, CAGR (2021-2028)
FIGURE 23 ASIA-PACIFIC HERPES MARKET : BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 24 ASIA-PACIFIC HERPES MARKET : BY DRUG TYPE, 2020
FIGURE 25 ASIA-PACIFIC HERPES MARKET : BY DRUG TYPE, 2019-2028 (USD MILLION)
FIGURE 26 ASIA-PACIFIC HERPES MARKET : BY DRUG TYPE, CAGR (2021-2028)
FIGURE 27 ASIA-PACIFIC HERPES MARKET : BY DRUG TYPE, LIFELINE CURVE
FIGURE 28 ASIA-PACIFIC HERPES MARKET: BY AGE, 2020
FIGURE 29 ASIA-PACIFIC HERPES MARKET: BY AGE, 2019-2028 (USD MILLION)
FIGURE 30 ASIA-PACIFIC HERPES MARKET: BY AGE, CAGR (2021-2028)
FIGURE 31 ASIA-PACIFIC HERPES MARKET: BY AGE, LIFELINE CURVE
FIGURE 32 ASIA-PACIFIC HERPES MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 33 ASIA-PACIFIC HERPES MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
FIGURE 34 ASIA-PACIFIC HERPES MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 35 ASIA-PACIFIC HERPES MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 36 ASIA-PACIFIC HERPES MARKET: DISTRIBUTION CHANNEL, 2020
FIGURE 37 ASIA-PACIFIC HERPES MARKET: DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
FIGURE 38 ASIA-PACIFIC HERPES MARKET: DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 39 ASIA-PACIFIC HERPES ASIA-PACIFIC MARKET: DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 40 ASIA-PACIFIC HERPES MARKET: BY END USERS, 2020
FIGURE 41 ASIA-PACIFIC HERPES MARKET: BYEND USERS, 2019-2028 (USD MILLION)
FIGURE 42 ASIA-PACIFIC HERPES MARKET: BY END USERS, CAGR (2021-2028)
FIGURE 43 ASIA-PACIFIC HERPES MARKET: BY END USERS, LIFELINE CURVE
FIGURE 44 ASIA-PACIFIC HERPES MARKET: SNAPSHOT (2020)
FIGURE 45 ASIA-PACIFIC HERPES MARKET: BY COUNTRY (2020)
FIGURE 46 ASIA-PACIFIC HERPES MARKET: BY COUNTRY (2021 & 2028)
FIGURE 47 ASIA-PACIFIC HERPES MARKET: BY COUNTRY (2020 & 2028)
FIGURE 48 ASIA-PACIFIC HERPES MARKET: BY VIRUS TYPE (2021-2028)
FIGURE 49 ASIA-PACIFIC HERPES MARKET: COMPANY SHARE 2020 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
